Hepatitis C virus entry: Role of host and viral factors

Infection, Genetics and Evolution

Volumn 12, Issue 8, 2012, Pages 1699-1709

  Samreen, Baila ^b   Khaliq, Saba ^a   Ashfaq, Usman Ali ^c   Khan, Mahwish ^b   Afzal, Nadeem ^a   Shahzad, Muhammad Aiman ^b   Riaz, Sabeen ^b   Jahan, Shah ^a  

^a UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^b UNIVERSITY OF THE PUNJAB   (Pakistan)

^c GOVERNMENT COLLEGE UNIVERSITY   (Pakistan)

Author keywords

HCV; HCV infection; HCV receptor; HCV therapeutic targets

Indexed keywords

ALPHA INTERFERON; BOCEPREVIR; CD209 ANTIGEN; CD81 ANTIGEN; CLAUDIN 1; GLYCOPROTEIN E1; GLYCOPROTEIN E2; GLYCOSAMINOGLYCAN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MEMBRANE PROTEIN; OCCLUDIN; PEGINTERFERON; PROTEIN 2WINT; PROTEIN CD5; PROTEIN EWI; PROTEIN L SIGN; PROTEIN NPC1L1; RIBAVIRIN; SCAVENGER RECEPTOR BI; SMALL INTERFERING RNA; TELAPREVIR; UNCLASSIFIED DRUG; VIRUS RNA;

CELL POLARITY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG TARGETING; GENE SILENCING; HEPATITIS C; HEPATITIS C VIRUS; HOST PATHOGEN INTERACTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIVER CELL; NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REPLICON; REVIEW; RNA INTERFERENCE; RNA REPLICATION; SIGNAL TRANSDUCTION; VIRUS ENTRY; VIRUS INFECTIVITY;

HEPACIVIRUS; HEPATITIS C; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; HUMANS; VIRUS INTERNALIZATION;

HEPATITIS C VIRUS;

EID: 84865849178     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2012.07.010     Document Type: Review

References (73)

1. Acton S.L., Scherer P.E., Lodish H.F., Krieger M. Expression cloning of SR-BI, a CD36-related class B scavenger receptor. J. Biol. Chem. 1994, 269:21003-21009.
2. Agnello V., Abel G., Elfahal M., Knight G.B., Zhang Q.X. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA 1999, 96:12766-12771.
3. Alter M.J., Margolis H.S., Krawczynski K., Judson F.N., Mares A., Alexander W.J., Hu P.Y., Miller J.K., Gerber M.A., Sampliner R.E., et al. The natural history of community-acquired hepatitis C in the United States. The sentinel counties chronic non-A, non-B hepatitis study team. N. Engl. J. Med. 1992, 327:1899-1905.
4. Andreo U., Maillard P., Kalinina O., Walic M., Meurs E., Martinot M., Marcellin P., Budkowska A. Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection. Cell Microbiol. 2007, 9:2445-2456.
5. Ashfaq U.A., Ansar M., Sarwar M.T., Javed T., Rehman S., Riazuddin S. Post-transcriptional inhibition of hepatitis C virus replication through small interference RNA. Virol. J. 2011, 8:112.
6. Ashfaq U.A., Khan S.N., Nawaz Z., Riazuddin S. In-vitro model systems to study Hepatitis C Virus. Genet. Vaccines Ther. 2011, 9:7.
7. Bartenschlager R., Ahlborn-Laake L., Mous J., Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J. Virol. 1993, 67:3835-3844.
8. Bartenschlager R., Penin F., Lohmann V., Andre P. Assembly of infectious hepatitis C virus particles. Trends Microbiol. 2011, 19:95-103.
9. Barth H., Schafer C., Adah M.I., Zhang F., Linhardt R.J., Toyoda H., Kinoshita-Toyoda A., Toida T., Van Kuppevelt T.H., Depla E., Von Weizsacker F., Blum H.E., Baumert T.F. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 2003, 278:41003-41012.
10. Bartosch B., Dubuisson J., Cosset F.L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 2003, 197:633-642.
11. Beglova N., Blacklow S.C. The LDL receptor: how acid pulls the trigger. Trends Biochem. Sci. 2005, 30:309-317.
12. Benedicto I., Molina-Jimenez F., Barreiro O., Maldonado-Rodriguez A., Prieto J., Moreno-Otero R., Aldabe R., Lopez-Cabrera M., Majano P.L. Hepatitis C virus envelope components alter localization of hepatocyte tight junction-associated proteins and promote occludin retention in the endoplasmic reticulum. Hepatology 2008, 48:1044-1053.
13. Bertaux C., Dragic T. Different domains of CD81 mediate distinct stages of hepatitis C virus pseudoparticle entry. J. Virol. 2006, 80:4940-4948.
14. Brazzoli M., Bianchi A., Filippini S., Weiner A., Zhu Q., Pizza M., Crotta S. CD81 is a central regulator of cellular events required for hepatitis C virus infection of human hepatocytes. J. Virol. 2008, 82:8316-8329.
15. Burlone M.E., Budkowska A. Hepatitis C virus cell entry: role of lipoproteins and cellular receptors. J. Gen. Virol. 2009, 90:1055-1070.
16. Cai Z., Cai L., Jiang J., Chang K.S., van der Westhuyzen D.R., Luo G. Human serum amyloid A protein inhibits hepatitis C virus entry into cells. J. Virol. 2007, 81:6128-6133.
17. Callens N., Ciczora Y., Bartosch B., Vu-Dac N., Cosset F.L., Pawlotsky J.M., Penin F., Dubuisson J. Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein E2 contribute to virus entry. J. Virol. 2005, 79:15331-15341.
18. Ciczora Y., Callens N., Penin F., Pecheur E.I., Dubuisson J. Transmembrane domains of hepatitis C virus envelope glycoproteins: residues involved in E1E2 heterodimerization and involvement of these domains in virus entry. J. Virol. 2007, 81:2372-2381.
19. Cocquerel L., Kuo C.C., Dubuisson J., Levy S. CD81-dependent binding of hepatitis C virus E1E2 heterodimers. J. Virol. 2003, 77:10677-10683.
20. Cocquerel L., Op de Beeck A., Lambot M., Roussel J., Delgrange D., Pillez A., Wychowski C., Penin F., Dubuisson J. Topological changes in the transmembrane domains of hepatitis C virus envelope glycoproteins. EMBO J. 2002, 21:2893-2902.
21. Cormier E.G., Durso R.J., Tsamis F., Boussemart L., Manix C., Olson W.C., Gardner J.P., Dragic T. L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc. Natl. Acad. Sci. USA 2004, 101:14067-14072.
22. Dreux, M., Dao Thi, V.L., Fresquet, J., Guerin, M., Julia, Z., Verney, G., Durantel, D., Zoulim, F., Lavillette, D., Cosset, F.L., Bartosch, B., 2009. Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains. PLoS Pathog. 5, e1000310.
23. Drummer H.E., Wilson K.A., Poumbourios P. Determinants of CD81 dimerization and interaction with hepatitis C virus glycoprotein E2. Biochem. Biophys. Res. Commun. 2005, 328:251-257.
24. Engering A., Van Vliet S.J., Geijtenbeek T.B., Van Kooyk Y. Subset of DC-SIGN(+) dendritic cells in human blood transmits HIV-1 to T lymphocytes. Blood 2002, 100:1780-1786.
25. Evans M.J., von Hahn T., Tscherne D.M., Syder A.J., Panis M., Wolk B., Hatziioannou T., McKeating J.A., Bieniasz P.D., Rice C.M. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. Nature 2007, 446:801-805.
26. Friebe P., Bartenschlager R. Role of RNA structures in genome terminal sequences of the hepatitis C virus for replication and assembly. J. Virol. 2009, 83:11989-11995.
27. Furuse M., Tsukita S. Claudins in occluding junctions of humans and flies. Trends Cell Biol. 2006, 16:181-188.
28. Gardner J.P., Durso R.J., Arrigale R.R., Donovan G.P., Maddon P.J., Dragic T., Olson W.C. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc. Natl. Acad. Sci. USA 2003, 100:4498-4503.
29. Gastaminza P., Cheng G., Wieland S., Zhong J., Liao W., Chisari F.V. Cellular determinants of hepatitis C virus assembly, maturation, degradation, and secretion. J. Virol. 2008, 82:2120-2129.
30. Geijtenbeek T.B., Kwon D.S., Torensma R., van Vliet S.J., van Duijnhoven G.C., Middel J., Cornelissen I.L., Nottet H.S., KewalRamani V.N., Littman D.R., Figdor C.G., van Kooyk Y. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000, 100:587-597.
31. Goffard A., Callens N., Bartosch B., Wychowski C., Cosset F.L., Montpellier C., Dubuisson J. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J. Virol. 2005, 79:8400-8409.
32. Helle F., Goffard A., Morel V., Duverlie G., McKeating J., Keck Z.Y., Foung S., Penin F., Dubuisson J., Voisset C. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J. Virol. 2007, 81:8101-8111.
33. Henry S.D., van der Wegen P., Metselaar H.J., Tilanus H.W., Scholte B.J., van der Laan L.J. Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes. Mol. Ther. 2006, 14:485-493.
34. Huang H., Sun F., Owen D.M., Li W., Chen Y., Gale M., Ye J. Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low-density lipoproteins. Proc. Natl. Acad. Sci. USA 2007, 104:5848-5853.
35. Ito M., Kusunoki H., Mochida K., Yamaguchi K., Mizuochi T. HCV infection and B-cell lymphomagenesis. Adv. Hematol. 2011, 2011:835314.
36. Jahan S., Khaliq S., Samreen B., Ijaz B., Khan M., Ahmad W., Ashfaq U.A., Hassan S. Effect of combined siRNA of HCV E2 gene and HCV receptors against HCV. Virol. J. 2011, 8:295.
37. Jahan S., Samreen B., Khaliq S., Ijaz B., Khan M., Siddique M.H., Ahmad W., Hassan S. HCV entry receptors as potential targets for siRNA-based inhibition of HCV. Genet. Vaccines Ther. 2011, 9:15.
38. Kasama Y., Sekiguchi S., Saito M., Tanaka K., Satoh M., Kuwahara K., Sakaguchi N., Takeya M., Hiasa Y., Kohara M., Tsukiyama-Kohara K. Persistent expression of the full genome of hepatitis C virus in B cells induces spontaneous development of B-cell lymphomas in vivo. Blood 2010, 116:4926-4933.
39. Khaliq S., Jahan S., Ijaz B., Ahmad W., Asad S., Hassan S. Inhibition of hepatitis C virus genotype 3a by siRNAs targeting envelope genes. Arch. Virol. 2011, 156:433-442.
40. Kolesnikova T.V., Stipp C.S., Rao R.M., Lane W.S., Luscinskas F.W., Hemler M.E. EWI-2 modulates lymphocyte integrin alpha4beta1 functions. Blood 2004, 103:3013-3019.
41. Kondo Y., Ueno Y., Shimosegawa T. Biological significance of HCV in various kinds of lymphoid cells. Int. J. Microbiol. 2012, 2012:647581.
42. Konopka G., Tekiela J., Iverson M., Wells C., Duncan S.A. Junctional adhesion molecule-A is critical for the formation of pseudocanaliculi and modulates E-cadherin expression in hepatic cells. J. Biol. Chem. 2007, 282:28137-28148.
43. Koutsoudakis G., Herrmann E., Kallis S., Bartenschlager R., Pietschmann T. The level of CD81 cell surface expression is a key determinant for productive entry of hepatitis C virus into host cells. J. Virol. 2007, 81:588-598.
44. Lavillette D., Pecheur E.I., Donot P., Fresquet J., Molle J., Corbau R., Dreux M., Penin F., Cosset F.L. Characterization of fusion determinants points to the involvement of three discrete regions of both E1 and E2 glycoproteins in the membrane fusion process of hepatitis C virus. J. Virol. 2007, 81:8752-8765.
45. Lindenbach B.D., Meuleman P., Ploss A., Vanwolleghem T., Syder A.J., McKeating J.A., Lanford R.E., Feinstone S.M., Major M.E., Leroux-Roels G., Rice C.M. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc. Natl. Acad. Sci. USA 2006, 103:3805-3809.
46. Liu M., Ding H., Zhao P., Qin Z.L., Gao J., Cao M.M., Luan J., Wu W.B., Qi Z.T. RNA interference effectively inhibits mRNA accumulation and protein expression of hepatitis C virus core and E2 genes in human cells. Biosci. Biotechnol. Biochem. 2006, 70:2049-2055.
47. Liu S., Yang W., Shen L., Turner J.R., Coyne C.B., Wang T. Tight junction proteins claudin-1 and occludin control hepatitis C virus entry and are downregulated during infection to prevent superinfection. J. Virol. 2009, 83:2011-2014.
48. Machida K., Cheng K.T., Pavio N., Sung V.M., Lai M.M. Hepatitis C virus E2-CD81 interaction induces hypermutation of the immunoglobulin gene in B cells. J. Virol. 2005, 79:8079-8089.
49. Machlin E.S., Sarnow P., Sagan S.M. Masking the 5' terminal nucleotides of the hepatitis C virus genome by an unconventional microRNA-target RNA complex. Proc. Natl. Acad. Sci. USA 2011, 108:3193-3198.
50. McCaffrey A.P., Meuse L., Pham T.T., Conklin D.S., Hannon G.J., Kay M.A. RNA interference in adult mice. Nature 2002, 418:38-39.
51. Mee C.J., Harris H.J., Farquhar M.J., Wilson G., Reynolds G., Davis C., van I.S.C., Balfe P., McKeating J.A. Polarization restricts hepatitis C virus entry into HepG2 hepatoma cells. J. Virol. 2009, 83:6211-6221.
52. Memon, A.R., Shafique, K., Memon, A., Draz, A.U., Rauf, M.U.A., Afsar, S., 2012. Hepatitis B and C prevalence among the high risk groups of Pakistani population. A cross sectional study. Arch. Public Health 70.
53. Mizuochi T., Ito M., Takai K., Yamaguchi K. Differential susceptibility of peripheral blood CD5+ and CD5- B cells to apoptosis in chronic hepatitis C patients. Biochem. Biophys. Res. Commun. 2009, 389:512-515.
54. Molina S., Castet V., Pichard-Garcia L., Wychowski C., Meurs E., Pascussi J.M., Sureau C., Fabre J.M., Sacunha A., Larrey D., Dubuisson J., Coste J., McKeating J., Maurel P., Fournier-Wirth C. Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. J. Virol. 2008, 82:569-574.
55. Nakagawa S., Umehara T., Matsuda C., Kuge S., Sudoh M., Kohara M. Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice. Biochem. Biophys. Res. Commun. 2007, 353:882-888.
56. Neumann A.U., Lam N.P., Dahari H., Gretch D.R., Wiley T.E., Layden T.J., Perelson A.S. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998, 282:103-107.
57. Nielsen S.U., Bassendine M.F., Burt A.D., Martin C., Pumeechockchai W., Toms G.L. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J. Virol. 2006, 80:2418-2428.
58. Panasiuk A., Parfieniuk A., Zak J., Flisiak R. Association among Fas expression in leucocytes, serum Fas and Fas-ligand concentrations and hepatic inflammation and fibrosis in chronic hepatitis C. Liver Int. 2009, 30:472-478.
59. Pekow J.R., Bhan A.K., Zheng H., Chung R.T. Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer 2007, 109:2490-2496.
60. Penin F., Dubuisson J., Rey F.A., Moradpour D., Pawlotsky J.M. Structural biology of hepatitis C virus. Hepatology 2004, 39:5-19.
61. Ploss A., Evans M.J., Gaysinskaya V.A., Panis M., You H., de Jong Y.P., Rice C.M. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009, 457:882-886.
62. Ray, K., 2012. Hepatitis: NPC1L1 identified as a novel HCV entry factor. Nature Reviews Gastroenterology and Hepatology.
63. Rocha-Perugini V., Montpellier C., Delgrange D., Wychowski C., Helle F., Pillez A., Drobecq H., Le Naour F., Charrin S., Levy S., Rubinstein E., Dubuisson J., Cocquerel L. The CD81 partner EWI-2wint inhibits hepatitis C virus entry. PLoS One 2008, 3:e1866.
64. Sainz B., Barretto N., Martin D.N., Hiraga N., Imamura M., Hussain S., Marsh K.A., Yu X., Chayama K., Alrefai W.A., Uprichard S.L. Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. Nat. Med. 2012, 18:281-285.
65. Sarhan M.A., Pham T.N., Chen A.Y., Michalak T.I. Hepatitis C virus infection of human T lymphocytes is mediated by CD5. J. Virol. 2012, 86:3723-3735.
66. Sarrazin C., Rouzier R., Wagner F., Forestier N., Larrey D., Gupta S.K., Hussain M., Shah A., Cutler D., Zhang J., Zeuzem S. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders. Gastroenterology 2007, 132:1270-1278.
67. Venkatraman S., Bogen S.L., Arasappan A., Bennett F., Chen K., Jao E., Liu Y.T., Lovey R., Hendrata S., Huang Y., Pan W., Parekh T., Pinto P., Popov V., Pike R., Ruan S., Santhanam B., Vibulbhan B., Wu W., Yang W., Kong J., Liang X., Wong J., Liu R., Butkiewicz N., Chase R., Hart A., Agrawal S., Ingravallo P., Pichardo J., Kong R., Baroudy B., Malcolm B., Guo Z., Prongay A., Madison V., Broske L., Cui X., Cheng K.C., Hsieh Y., Brisson J.M., Prelusky D., Korfmacher W., White R., Bogdanowich-Knipp S., Pavlovsky A., Bradley P., Saksena A.K., Ganguly A., Piwinski J., Girijavallabhan V., Njoroge F.G. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J. Med. Chem. 2006, 49:6074-6086.
68. von Hahn T., Yoon J.C., Alter H., Rice C.M., Rehermann B., Balfe P., McKeating J.A. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007, 132:667-678.
69. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11:791-796.
70. Yang W., Qiu C., Biswas N., Jin J., Watkins S.C., Montelaro R.C., Coyne C.B., Wang T. Correlation of the tight junction-like distribution of Claudin-1 to the cellular tropism of hepatitis C virus. J. Biol. Chem. 2008, 283:8643-8653.
71. Zeisel M.B., Koutsoudakis G., Schnober E.K., Haberstroh A., Blum H.E., Cosset F.L., Wakita T., Jaeck D., Doffoel M., Royer C., Soulier E., Schvoerer E., Schuster C., Stoll-Keller F., Bartenschlager R., Pietschmann T., Barth H., Baumert T.F. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology 2007, 46:1722-1731.
72. Zheng A., Yuan F., Li Y., Zhu F., Hou P., Li J., Song X., Ding M., Deng H. Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. J. Virol. 2007, 81:12465-12471.
73. Zuckerman E., Slobodin G., Kessel A., Sabo E., Yeshurun D., Halas K., Toubi E. Peripheral B-cell CD5 expansion and CD81 overexpression and their association with disease severity and autoimmune markers in chronic hepatitis C virus infection. Clin. Exp. Immunol. 2002, 128:353-358.